Show simple item record

dc.contributor.authorBergueiro, Julián
dc.contributor.authorGlitscher, Emanuel A.
dc.contributor.authorCalderón, Marcelo
dc.date.accessioned2023-03-22T16:30:55Z
dc.date.available2023-03-22T16:30:55Z
dc.date.issued2022-06
dc.identifier.citationBiomaterials Advances 137 : (2022) // Article ID 212842es_ES
dc.identifier.issn2772-9508
dc.identifier.urihttp://hdl.handle.net/10810/60448
dc.description.abstractTemperature-trigger chemotherapy is one of the state-of-the-art anti-tumoral strategies in nanomedicine. However, this strategy is in close relationship with the effect of the temperature in the tumor tissue. With high temperatures, the ablation of the tumor tissue can hinder a correct chemotherapy approximation. On the other hand, with moderate temperatures a negative vascularization that promotes the tumor growing is produced and competes with the chemotherapeutic effects. We have constructed one nanogel system composed of a thermoresponsive polymer cross-linked by plasmonic gold nanoparticles (AuNPs) for temperature-trigger chemotherapy. Doxorubicin loaded in the porous interior of the nanogel is released when the thermoresponsive network of the nanogel collapses due to the heat generated by the AuNPs upon near infra-red light irradiation. The hybrid nanogel system has been tested in vitro and in vivo, where it was observed that the temperatures reached in the in vivo NIR irradiation have an undesired effect on the inhibition of the tumor growth while the drug loaded systems considerably reduced the tumor sizes. This study shows the importance of design in temperature triggered antitumoral systems, where lower temperatures usually reached in practical situations due to light attenuation produced by the tissue can be positively utilized for enhancing the antitumoral effect of loaded drugs in the system.es_ES
dc.description.sponsorshipWe gratefully acknowledge financial support from the Bundesministerium für Bildung und Forschung (BMBF) through the NanoMatFutur award (13N12561, Thermonanogele). We would like to acknowledge the assistance of the Core Facility BioSupraMol supported by the Deutsche Forschungsgemeinschaft (DFG).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectnanogelses_ES
dc.subjectthermoresponsivees_ES
dc.subjectgold nanoparticleses_ES
dc.subjectphotothermal agentes_ES
dc.subjectcancer therapyes_ES
dc.subjectnanocarrieres_ES
dc.subjectdrug deliveryes_ES
dc.titleA hybrid thermoresponsive plasmonic nanogel designed for NIR-mediated chemotherapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2772950822001194?via%3Dihubes_ES
dc.identifier.doi10.1016/j.bioadv.2022.212842


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Except where otherwise noted, this item's license is described as © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).